Table 3.
Comparison of baseline ocular characteristics by geographic atrophy status in the study eyea
| Ocular Characteristic | Never developed GA N=33 N (%) |
Developed new GA N=7 N (%) |
GA present at baseline N=22 N (%) |
Ocular Characteristic | Never developed GA N=33 N (%) |
Developed new GA N=7 N (%) |
GA present at baseline N=22 N (%) |
|---|---|---|---|---|---|---|---|
| Visual Acuity | Previous Treatment | ||||||
| 20/25–20/40 | 15 (45.5) | 1 (14.3) | 9 (40.9) | Treatment naïve | 11 (33.3) | 1 (14.3) | 9 (40.9) |
| 20/50–20/80 | 10 (30.3) | 1 (14.3) | 7 (31.8) | PDT + injectionsb | 0 | 1 (14.3) | 3 (13.6) |
| 20/100–20/160 | 5 (15.1) | 4 (57.1) | 6 (27.3) | Injectionsb only | 20 (60.7) | 4 (57.1) | 10 (45.5) |
| 20/200–20/320 | 2 (6.1) | 1 (14.3) | 0 | Focal laser | 1 (3.0) | 0 | 0 |
| <20/400 | 1 (3.0) | 0 | 0 | Unknown | 1 (3.0) | 1 (14.3) | 0 |
| CNV Classification | CNV size on ICG (mm2) | ||||||
| Classic | 4 (12.1) | 0 | 5 (22.7) | 0–2.5 | 21 (63.6) | 3 (42.8) | 13 (59.1) |
| Minimally classic | 9 (27.3) | 3 (42.8) | 6 (27.3) | 2.6–5.0 | 5 (15.2) | 2 (28.6) | 6 (27.3) |
| Occult | 20 (60.6) | 2 (28.6) | 10 (45.5) | 5.1–7.5 | 2 (6.0) | 0 | 2 (9.1) |
| RAP | 0 | 1 (14.3) | 1 (4.5) | Indeterminate | 5 (15.2) | 2 (28.6) | 1 (4.5) |
| Indeterminate | 0 | 1 (14.3) | 0 | ||||
| Foveal fluid | Epiretinal membrane | ||||||
| Present | 29 (87.9) | 0 | 19 (86.4) | Present | 3 (9.1) | 0 | 4 (18.2) |
| Absent | 4 (12.1) | 7 (100) | 3 (13.6) | Absent | 29 (87.9) | 7 (100) | 18 (81.8) |
| Unknown | 1 (3.0) | 0 | 0 | ||||
GA: geographic atrophy; CNV: choroidal neovascularization; RAP: retinal angiomatous proliferation; PDT: photodynamic therapy; ICG: indocyanine green angiography
a
63 study eyes included in this analysis due to exclusion of 6 eyes for ungradeable baseline photos
b
Injections include intravitreal bevacizumab, ranibizumab, steroids, sirolimus, and pegaptanib